Zobrazeno 1 - 10
of 409
pro vyhledávání: '"Michael R. Verneris"'
Autor:
Michael D. Keller, Patrick J. Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C. Dvorak, Michael R. Verneris, Donald B. Kohn, Sung-Yun Pai, Blachy J. Dávila Saldaña, Benjamin Hanisch, Troy C. Quigg, Roberta H. Adams, Ann Dahlberg, Shanmuganathan Chandrakasan, Hasibul Hasan, Jemily Malvar, Mariah A. Jensen-Wachspress, Christopher A. Lazarski, Gelina Sani, John M. Idso, Haili Lang, Pamela Chansky, Chase D. McCann, Jay Tanna, Allistair A. Abraham, Jennifer L. Webb, Abeer Shibli, Amy K. Keating, Prakash Satwani, Pawel Muranski, Erin Hall, Michael J. Eckrich, Evan Shereck, Holly Miller, Ewelina Mamcarz, Rajni Agarwal, Satiro N. De Oliveira, Mark T. Vander Lugt, Christen L. Ebens, Victor M. Aquino, Jeffrey J. Bednarski, Julia Chu, Suhag Parikh, Jennifer Whangbo, Michail Lionakis, Elias T. Zambidis, Elizabeth Gourdine, Catherine M. Bollard, Michael A. Pulsipher
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed a phase II multicenter stud
Externí odkaz:
https://doaj.org/article/fcdca2f7424c452f994b7e545a14509b
Autor:
Ryotaro Nakamura, Corinna La Rosa, Dongyun Yang, Joshua A. Hill, Armin Rashidi, Hannah Choe, Qiao Zhou, Chetan Raj Lingaraju, Teodora Kaltcheva, Jeffrey Longmate, Jennifer Drake, Cynthia Slape, Lupe Duarte, Monzr M. Al Malki, Vinod A. Pullarkat, Ahmed Aribi, Steven Devine, Michael R. Verneris, Jeffrey S. Miller, Stephen J. Forman, Ibrahim Aldoss, Don J. Diamond
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/cf1ae355426e485785e84cba31e586c8
Autor:
Valentin Barsan, Yimei Li, Snehit Prabhu, Christina Baggott, Khanh Nguyen, Holly Pacenta, Christine L. Phillips, Jenna Rossoff, Heather Stefanski, Julie-An Talano, Amy Moskop, Susanne Baumeister, Michael R. Verneris, Gary Douglas Myers, Nicole A. Karras, Stacy Cooper, Muna Qayed, Michelle Hermiston, Prakash Satwani, Christa Krupski, Amy Keating, Vanessa Fabrizio, Vasant Chinnabhandar, Michael Kunicki, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch, Liora M. Schultz
Publikováno v:
EClinicalMedicine, Vol 65, Iss , Pp 102268- (2023)
Summary: Background: Tisagenlecleucel was approved by the Food and Drug Administration (FDA) in 2017 for refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-ALL in ≥2nd relapse. Outcomes of patients receiving commercial tisagenlecleucel up
Externí odkaz:
https://doaj.org/article/20c0403244324301a828fb1de6d7904b
Autor:
Joselyn Cruz Cruz, Kristen C. Allison, Lauren S. Page, Alexis J. Jenkins, Xiaodong Wang, H. Shelton Earp, Stephen V. Frye, Douglas K. Graham, Michael R. Verneris, Alisa B. Lee-Sherick
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundPrevious studies show that the spleen and bone marrow can serve as leukemia microenvironments in which macrophages play a significant role in immune evasion and chemoresistance. We hypothesized that the macrophage driven tolerogenic process
Externí odkaz:
https://doaj.org/article/6c936b3c3cbd434da91afc7829838a3a
Autor:
Peter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E. Woolfrey, Merav Bar, Michael R. Verneris, Michael J. Borowitz, Nirali N. Shah, Nathan Gossai, Peter J. Shaw, Allen R. Chen, Kirk R. Schultz, Hermann Kreyenberg, Lucia Di Maio, Gianni Cazzaniga, Cornelia Eckert, Vincent H.J. van der Velden, Rosemary Sutton, Arjan Lankester, Christina Peters, Thomas E. Klingebiel, Andre M. Willasch, Stephan A. Grupp, Michael A. Pulsipher
Publikováno v:
Blood Advances, Vol 3, Iss 21, Pp 3393-3405 (2019)
Abstract: Detection of minimal residual disease (MRD) pre– and post–hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) has been associated with relapse and poor survival. Published studies have had insuffici
Externí odkaz:
https://doaj.org/article/53bb75b719364b6dba97e0eeac5290e5
Autor:
Amy K. Keating, Nathan Gossai, Christine L. Phillips, Kelly Maloney, Kristen Campbell, Andrew Doan, Deepa Bhojwani, Michael J. Burke, Michael R. Verneris
Publikováno v:
Blood Advances, Vol 3, Iss 13, Pp 1926-1929 (2019)
Externí odkaz:
https://doaj.org/article/4412f34b34974ab999946ef0e2cb7a47
Autor:
Juan A. Marín-Jiménez, Anna Capasso, Matthew S. Lewis, Stacey M. Bagby, Sarah J. Hartman, Jeremy Shulman, Natalie M. Navarro, Hui Yu, Chris J. Rivard, Xiaoguang Wang, Jessica C. Barkow, Degui Geng, Adwitiya Kar, Ashley Yingst, Dejene M. Tufa, James T. Dolan, Patrick J. Blatchford, Brian M. Freed, Raul M. Torres, Eduardo Davila, Jill E. Slansky, Roberta Pelanda, S. Gail Eckhardt, Wells A. Messersmith, Jennifer R. Diamond, Christopher H. Lieu, Michael R. Verneris, Jing H. Wang, Katja Kiseljak-Vassiliades, Todd M. Pitts, Julie Lang
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500 clinical trials are currently ongoing with a goal of i
Externí odkaz:
https://doaj.org/article/6424fe4cd62341bb904d284bc361adfc
Autor:
Laura M. Cobb, Michael R. Verneris
Publikováno v:
JCI Insight, Vol 6, Iss 6 (2021)
Since their relatively recent discovery, innate lymphoid cells (ILCs) have been shown to be tissue-resident lymphocytes that are critical mediators of tissue homeostasis, regeneration, and pathogen response. However, ILC dysregulation contributes to
Externí odkaz:
https://doaj.org/article/47d3b9b1cdcd463aacea1756a6e02d88
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
For many pediatric sarcoma patients, multi-modal therapy including chemotherapy, radiation, and surgery is sufficient to cure their disease. However, event-free and overall survival rates for patients with more advanced disease are grim, necessitatin
Externí odkaz:
https://doaj.org/article/35d9101979f94b0bbad413b66aa50acc
Autor:
June Baik, Martin Felices, Ashley Yingst, Charles P. Theuer, Michael R. Verneris, Jeffrey S. Miller, Rita Perlingeiro
Publikováno v:
Heliyon, Vol 6, Iss 10, Pp e05242- (2020)
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refracto
Externí odkaz:
https://doaj.org/article/46178ff1423c45c780f5cb265e2f0868